What to look for in AI Healthcare Investments With: Krish Ramadurai
In this in-depth interview, Krish Ramadurai, Partner at AIX Ventures, shares his perspective on what's real and what's overhyped in AI development in healthcare. He explains the importance of domain expertise, the role of clinical workflow automation, and why business models must align with enterprise value creation. Ramadurai also discusses AI’s role in drug development, the challenge of regulatory compliance, and the strategic investments that drive sustainable innovation. His insights provide a roadmap for healthcare leaders navigating AI investment opportunities.
Episode Contents:
About the Guest
Krish Ramadurai is a Partner at AIX Ventures, specializing in investments at the intersection of AI and healthcare.
Key Takeaways
- AI should focus on specific healthcare subdomains
- Domain expertise is critical for market adoption
- Proprietary data is a key competitive advantage
Transcript Summary
Q: What's real in healthcare AI today versus hype? A: Domain expertise and workflow automation have real value. AI must integrate seamlessly into healthcare systems. Q: How can AI companies scale beyond pilots? A: Clear business models and measurable ROI are essential to transition from pilots to enterprise contracts. Q: What drives success in AI drug development? A: Start with human biology data, ensure diversity in datasets, and prioritize translational success in clinical trials.
More Topics
- AI in Patient Care
- AI in the Healthcare Industry
- AI and Medical Innovation
- Healthcare Ethics and Policy
Keep Exploring
About the Series
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine.
Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine.
Mika Newton is an expert in healthcare data management, with a focus on data completeness and universality. Mika is on the editorial board of AI in Precision Oncology and is no stranger to bringing transformative technologies to market and fostering innovation.